Atreca shares are trading lower after the company announced the sale of a collection of antibody-related assets and materials to Immunome consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones.
Portfolio Pulse from Benzinga Newsdesk
Atreca, Inc. (BCEL) shares dropped following the announcement of selling antibody-related assets to Immunome for $5.5 million upfront and potential $7 million in milestones.
December 26, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atreca's stock price is likely to experience downward pressure in the short term due to the sale of assets, which may be perceived as a need for cash or a strategic pivot.
The sale of assets often leads to a negative perception among investors, as it can indicate a need for liquidity or a change in business direction. The immediate cash infusion is typically less than the potential long-term value of the assets, which can lead to a short-term decrease in stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80